RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

Benzinga Newsdesk www.benzinga.com Negative 95.4%

Neg 95.4% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $14 to $13.